Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension

BACKGROUND: Droxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there is limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks of treatment. OBJECTIVE: Examine the real‐world experience of patients taki...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mov Disord Clin Pract
Asıl Yazarlar: François, Clément, Shibao, Cyndya A., Biaggioni, Italo, Duhig, Amy M., McLeod, Kim, Ogbonnaya, Augustina, Quillen, Apryl, Cannon, Joan, Padilla, Byron, Yue, Binglin, Orloski, Laurie, Kymes, Steven M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2019
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6417751/
https://ncbi.nlm.nih.gov/pubmed/30949555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12726
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller